| PAUL-EHRLICH-INSTITUT BUNDESAMT FUR SERA UND IMPFSTOFFE Patent applications |
| Patent application number | Title | Published |
|---|
| 20110033837 | IMMORTALIZED HUMAN CD4-POSITIVE CELL AND ITS USE FOR DETERMINING THE PHENOTYPE OF A HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 - The invention relates to an immortalized CD4-positive cell. According to the invention, this cell comprises a gene encoding a CXCR4 chemokine receptor that is capable of serving as a coreceptor for entry of a Human Immunodeficiency Virus Type 1 (HIV-I) into the cell, and a gene encoding a CCR5 receptor that is not capable of serving as a coreceptor for entry of a Human Immunodeficiency Virus Type 1 into the cell. The invention furthermore relates to a method for the phenotypical characterization of a HIV-I, comprising providing such a cell, adding an HIV-I to the cell under conditions that allow for the entrance of the HIV-I into the cell and the replication of the virus in the cell, and measuring the replication of the HIV-I in the cell. | 02-10-2011 |
| 20110020391 | RECOMBINANT MODIFIED VACCINIA VIRUS ANKARA (MVA)-BASED VACCINE FOR THE AVIAN FLU - The present invention relates to the use of a recombinant modified vaccinia virus Ankara (MVA) comprising a heterologous nucleic acid for the production of a medicament in particular a vaccine, wherein the sequence of heterologous nucleic acid is from influenza A virus class H5 antigen. In a further aspect of the invention the invention relates to a recombinant modified vaccinia virus Ankara (MVA) comprising a heterologous nucleic acid, wherein (a) the heterologous nucleic acid is incorporated into a non-essential site within the genome of MVA, (b) the heterologous nucleic acid is under the control of a vaccinia virus promoter, or orthopoxvirus promoter, or poxvirus-specific promoter and, (c) the heterologous nucleic acid is selected from the group of nucleic acids encoding a gene or a part of a gene from an influenza A virus class H5. | 01-27-2011 |
